Akeso Enrolls First Patient in Global Phase III Trial for Gastric Cancer Treatment

In a major advancement in cancer research, Akeso, Inc. has announced the enrollment of its first patient in the global COMPASSION-37 trial (AK104-311), aimed at evaluating cadonilimab, a groundbreaking PD-1/CTLA-4 bispecific antibody. This trial seeks to compare the efficacy of cadonilimab in conjunction with chemotherapy against the combination of chemotherapy and nivolumab in treating patients with HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who have not received prior treatment.

The COMPASSION-37 study is significant as it aims to assess both the efficacy and safety of cadonilimab as a first-line treatment for advanced gastric cancer across various geographic and ethnic populations around the world. By considering patient diversity, the study investigates whether the dual blockade of PD-1 and CTLA-4 can significantly enhance treatment outcomes beyond the current standard.

The trial is co-led by a host of prominent international researchers, including Dr. Yelena Y. Janjigian from Memorial Sloan Kettering Cancer Center, who has a substantial background in gastrointestinal oncology, having previously contributed to the establishment of standard treatments for this disease. Moreover, the involvement of esteemed professionals from renowned institutions across the globe indicates the high stakes and potential impact of this study.

Dr. Janjigian remarked on the transformative potential of cadonilimab, stating, "Immunotherapy has greatly improved the longevity and quality of life for patients suffering from stomach and esophageal cancers. Our objective in evaluating cadonilimab is to better understand its capacity to enhance patient outcomes and promote long-term survival."

Research has highlighted the critical role of PD-L1 expression levels in determining the effectiveness of PD-1 inhibitors, with heightened benefits clearly observed in patients exhibiting high PD-L1 levels. Nevertheless, the clinical community is keen to establish treatment options for those with low PD-L1 expression, an area that remains largely unaddressed. Currently, the standard treatment for advanced gastric cancer involves chemotherapy alone or in combination with PD-1 inhibitors, yet this approach is predominantly effective for PD-L1-positive patients only, underscoring a substantial clinical gap.

Professor Jiafu Ji from Peking University emphasized that earlier studies have demonstrated cadonilimab combined with chemotherapy significantly enhances overall survival for patients with HER2-negative advanced gastric cancer, especially those with PD-L1 expression less than 5. This reinforces the potential for dual blockade therapy not only to broaden the scope of candidates for immunotherapy but also to provide valid alternatives to international treatment standards. Ji stated, "The challenge we face as clinicians is to identify whether such innovative therapies can deliver substantial benefits across various PD-L1 levels and diverse populations globally."

Moving from the highly controlled environment of COMPASSION-15 studies in China, where volunteer cohorts showed promising results, to the expansive, multicenter nature of COMPASSION-37 enhances the chances of generating reliable and widely applicable findings. The goal is to determine whether cadonilimab can deliver improved patient survival rates compared to existing treatment standards with a specific focus on patients expressing low PD-L1 levels.

Looking ahead, Akeso is also involved in additional studies exploring cadonilimab's potential in other settings, including a Phase II trial evaluating the drug in the perioperative context alongside chemotherapy for patients with locally advanced, resectable gastric or gastroesophageal junction tumors.

As the landscape of gastric cancer treatment develops, cadonilimab stands at the forefront as a promising candidate for addressing both current shortcomings in immunotherapy and the complexities of various patient responses based on individual biological characteristics. Should the COMPASSION-37 trial yield positive outcomes, cadonilimab may well reshape the standard of care for gastric cancer, potentially providing relief for a wider array of patients who are currently limited in their treatment options.

In conclusion, this trial could mark a significant milestone for both Akeso and the medical community at large, highlighting the evolving landscape of gastric cancer treatment and illuminating promising pathways for patient care in this challenging arena.